Prezista darunavir regulatory update

Johnson & Johnson's Tibotec Pharmaceuticals Ltd. unit issued a "Dear Healthcare Professional" letter and updated the label of HIV drug Prezista darunavir to warn of the risk of hepatotoxicity. The co...